Eric first experienced eczema symptoms while in his 50's, where the itch and inflammation bothered him daily, from work to the golf course. Hear how Eric sought relief from his symptoms with the help of his dermatologist and OPZELURA.
Individual results may vary. OPZELURA is not for everyone.
ERIC VIDEO DESCRIPTIVE TRANSCRIPT
(DESCRIPTION)
The rumble of a garage door and hum of a guitar begin as Eric opens his garage door, revealing his workshop.
(ON-SCREEN TEXT)
This video is brought to you by Incyte.
ERIC:
As an electrician, I'm very dependent on being able to use my hands—
(DESCRIPTION)
A montage of electrical tools move across the screen before we see Eric working with practiced focus, the guitar rising.
ERIC:
stripping wire or bending conduit. Thank God this didn't affect me earlier. I don't know where I'd be because it would've changed my whole career path.
(ON-SCREEN TEXT)
ERIC
LIVING WITH ECZEMA
ERIC:
I have mild to a moderate eczema—definitely surprised to get it this late in life. I would've assumed that a skin condition is probably something that develops young and stays with you your whole life. That's not what happened with me. When I first started noticing symptoms of my eczema was in Florida. Actually, I was on vacation and a spot appeared on my hip, moved to a couple of different spots on my body, my legs. I think the biggest thing was the itching.
(DESCRIPTION)
Tangled wires with frayed ends buzz with electricity.
ERIC:
I mean, I couldn't help it. I would be in public just digging or digging on my arm and then I'd start bleeding and then my wife was always yelling at me—knock that off. I mean, it's easier said than done. I had cream on my hands all the time. I had open sores. It kept me from working with my hands because I couldn't turn a screwdriver and I couldn't open a jar. I was using over the counter creams constantly. Five or six times a day I would put lotion on, and I'm not kidding you literally 10 minutes later I'd be putting lotion on again. I'm not a very good golfer, but I do enjoy it. I try to get a couple rounds a week. The people I played with were like, what's going on with your hands guy? And be wrapping them several times around, so I couldn't grip anything. It pretty much affected everything I did.
(DESCRIPTION)
A golf ball rolls off-screen as the screen blurs, guitar strumming as it exits.
ERIC:
It got to the point where I was sleeping in rubber gloves, wake up, digging on my leg, and not be able to stay asleep at night. It was a pretty bad time in my life. Finally went to a different dermatologist and he gave me a sample tube of OPZELURA.
(DESCRIPTION)
The guitar beat lifts as it is joined by other instruments as Eric tees up in a garage-sized putting green.
NARRATOR:
OPZELURA is a treatment for mild to moderate eczema.
(ON-SCREEN TEXT)
OPZELURA® (ruxolitinib) cream 1.5% is a treatment for mild to moderate eczema. For short-term, non-continuous treatment in people 12 and older without weakened immune systems and not well controlled on topical Rx therapies or when therapies are not recommended.
NARRATOR:
OPZELURA can lower your ability to fight infections, including TB or hepatitis B or C,
(ON-SCREEN TEXT)
Before starting OPZELURA, tell your doctor if you have an infection, are being treated for one, have TB or have been in close contact with someone with TB; or had Hepatitis B or C.
NARRATOR:
serious lung infections, skin cancer, blood clots, and low blood cell counts
(ON-SCREEN TEXT)
Your doctor should check for infections before and during treatment.
NARRATOR:
occurred with OPZELURA and people taking JAK inhibitors.
(ON-SCREEN TEXT)
Tell your doctor if you had blood clots in your legs or lungs. OPZELURA may cause low platelets, low red and white blood cell counts.
NARRATOR:
Serious infections, increased risk of death, lymphoma, other cancers, and major cardiovascular events have occurred. The most common side effect was the common cold.
(ON-SCREEN TEXT)
OPZELURA is a topical JAK inhibitor. People 50 and older with at least 1 heart disease risk factor have an increased risk of heart attack, stroke, blood clots, and death while taking JAK inhibitors by mouth.
ERIC:
It wasn't long before I started noticing the itching going away. Um, the lesions I had on my—certain spots on my hands were clearing up. I mean, it's just, it's been wonderful. I mean, it-it has.
(ON-SCREEN TEXT)
OPZELURA will not work for everyone. In a medical study of mild to moderate atopic dermatitis, 54% of patients had clear to almost clear skin at 8 weeks and 52% of patients had a significant reduction in their itch, compared to 15% of patients who used a cream that did not contain medication.
ERIC:
The first time that I took my club outta my bag and I didn't have to put cream on—
(ON-SCREEN TEXT)
Some people saw rapid itch improvement as early as 3 or 4 days. Results may vary. See results at OPZELURA.com.
ERIC:
and bandage up my hand and my buddies were like, I can't believe your hands. I would say that was my aha moment.
(ON-SCREEN TEXT)
If you are using OPZELURA for atopic dermatitis, stop using OPZELURA when your signs and symptoms of atopic dermatitis, such as itching, rash, and redness go away, or as directed by your healthcare provider. Tell your healthcare provider if your symptoms do not improve within 8 weeks of treatment.
ERIC:
For me, it was, I'm not searching for something to help me out anymore. I found it.
(ON-SCREEN TEXT)
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
ERIC:
I know there's a lot of people that probably haven't found relief yet. I just wanna encourage them to, to stay the course. Certainly ask your doctor about OPZELURA. Help is out there and I'm glad that I found it and they can too.
(ON-SCREEN TEXT)
For topical use only. Do not use in your eyes, mouth, or vagina. Apply twice daily as directed.
NARRATOR:
OPZELURA is a prescription medicine used on the skin (topical) for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis.
OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.
OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.
Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.
Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.
Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.
Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.
Before starting OPZELURA, tell your healthcare provider if you:
After starting OPZELURA:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).
These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.
Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.
[END OF TRANSCRIPT]
OPZELURA is a prescription medicine used on the skin (topical) for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis.
OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina.
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.
OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.
Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen.
Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth.
Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.
Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.
Before starting OPZELURA, tell your healthcare provider if you:
After starting OPZELURA:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).
These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.
Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.
